Thrombocytopenia from combination treatment with oseltamivir and probenecid: Case report, medwatch data summary, and review of the literature

Pharmacotherapy

Volumn 29, Issue 8, 2009, Pages 988-992

  Raisch, Dennis W ^a   Straight, Timothy M ^b   Holodniy, Mark ^c  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Oseltamivir; Probenecid; Thrombocytopenia

Indexed keywords

ACETYLSALICYLIC ACID; IMMUNOGLOBULIN; OSELTAMIVIR; PROBENECID; STEROID;

AGED; ANAMNESIS; ARTICLE; BLEEDING; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; PHYSICAL EXAMINATION; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTIVIRAL AGENTS; DRUG INTERACTIONS; FEMALE; HUMANS; OSELTAMIVIR; PROBENECID; THROMBOCYTOPENIA;

EID: 68149170664     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.29.8.988     Document Type: Article

References (20)

1. Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res 2008;78:91-102.
2. Holodniy M, Penzak SR, Straight TM, et al. Pharmacokinetics and tolerability of oseltamivir combined with probenecid. Antimicrob Agents Chemother 2008;52:3013-3021
3. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245
4. Chokephaibulkit K, Uiprasertkul M, Puthavathana P, et al. A child with avian influenza A (H5N1) infection. Pediatr Infect Dis J 2005;24:162-166 (Pubitemid 40250776)
5. Tishler M, Levy O, Amit-Vazina M. Immune thrombocytopenic purpura following influenza vaccination. Isr Med Assoc J 2006;8:322-323 (Pubitemid 43805047)
6. Areechokchai D, Jiraphongsa C, Laosiritaworn Y, Hanshaoworakul W, O'Reilly M. Investigation of avian influenza (H5N1) outbreak in humans - Thailand, 2004. MMWR Morb Mortal Wkly Rep 2006;55(suppl 1):3-6.
7. Jih DM, Werth VP. Thrombocytopenia after a single test dose of methotrexate. J Am Acad Dermatol 1998;39:349-351
8. Chung SH, Kim MJ, Lee JY, Chung JH. Effects of probenecid on platelet aggregation and cytotoxicity: drawbacks of the use of probenecid in monitoring intracellular calcium metabolism. Thromb Res 1997;85:345-350
9. Packham MA, Rand ML, Perry DW, Ruben DH, Kinlough-Rathbone RL. Probenecid inhibits platelet responses to aggregating agents in vitro and has a synergistic inhibitory effect with penicillin G. Thromb Haemost 1996;76:239-244
10. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Tamiflu (oseltamivir) labeling, 2008. Available from http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search.Overview&DrugName=TAMIFLU. Accessed April 6, 2009.
11. RX med. Benemed (probenecid) labeling, 2009. Available from http://www.rxmed.com/b.main/b2.pharmaceutical/b2.1.monographs /CPS-%20Monographs/CPS-20(General%20Monographs-%20B)/BENEMID.html. Accessed April 6, 2009.
12. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001;10:483-486 (Pubitemid 34100774)
13. DuMouchel W, Smith ET, Beasley R, et al. Association of asthma therapy and Churg-Strauss syndrome: an analysis of postmarketing surveillance data. Clin Ther 2004;26:1092-1104 (Pubitemid 39141812)
14. Curtis JR, Cheng H, Delzell E, et al. Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example. Med Care 2008;46:969-975
15. Backstrom M, Mjorndal T, Dahlqvist R. Under-reporting of serious adverse drug reactions in Sweden. Pharmacoepidemiol Drug Saf 2004;13:483-487 (Pubitemid 38996859)
16. Pierfitte C, Begaud B, Lagnaoui R, Moore ND. Is reporting rate a good predictor of risks associated with drugs? Br J Clin Pharmacol 1999;47:329-331
17. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006;29:385-396 (Pubitemid 43752541)
18. Sjolinder M, Tornhamre S, Claesson HE, Hydman J, Lindgren J. Characterization of a leukotriene C4 export mechanism in human platelets: possible involvement of multidrug resistance-associated protein 1. J Lipid Res 1999;40:439-446 (Pubitemid 29116147)
19. Ozaki Y, Matsumoto Y, Yatomi Y, Higashihara M, Kariya T, Shoji K. Effects of five anion channel blockers on thrombin-and ionomycin-activated platelet functions. Biochem Pharmacol 1989;38:2147-2152 (Pubitemid 19171216)
20. van't Veer C, van der Poll T. Keeping blood clots at bay in sepsis. Nat Med 2008;14:606-608